



Ravenscroft Investment Fund Offshore

Global Blue Chip Fund

INVESTMENT MANAGERS: RAVENSCROFT INVESTMENT MANAGEMENT LIMITED

THEME WEIGHTINGS



32	Healthcare
	- Pharmaceuticals
	- Medical Devices
30	Global Brands
	- Consumer Staples
	- Consumer Discretionary


27	Technology & Innovation
	- Information Technology
	- Engineering & Industrials
11	Cash & Equivalents

FUND AIMS AND OBJECTIVES

The Global Blue Chip Fund's main objective is to generate long-term capital growth from a focused portfolio of large global businesses, which are listed on recognised stock exchanges in developed countries. It is actively managed and not constrained by a benchmark.

Ravenscroft Global Blue Chip is a sub-fund of the Ravenscroft Investment Fund Offshore; an open-ended, multi-class Unit Trust authorised as a Class B Scheme by the Guernsey Financial Services Commission.

PERFORMANCE CHART



FUND SIZE: £126.0 M

Past performance is not a reliable indicator of future results.

FUND MANAGER COMMENTARY

Your Fund returned 3.6% during the month bringing the year-to-date return to 11.5%. By comparison, the MSCI World Index returned 4.4% during the month driven, primarily, by the strong performance of the Information Technology (+10.0%), Energy (+6.1%) and Healthcare (+6.1%) sectors. Your Fund has no exposure to the energy sector and the allocation to technology stocks is smaller than that of the index component (Approx 13.5% versus 22%). From an asset allocation perspective, this would have provided a headwind during the month. In addition to this, stock selection within the technology component also detracted. The Fund's basket of technology stocks returned 5.4% during the month with only Dropbox (+13.7%) and Microsoft

(+11.4%) outperforming the benchmark component.

The Fund's top contributor was Roche, returning 11.6% in GBP and contributing 0.5% to the overall Fund performance. The strong performance recently does not appear to be as a result of any stock specific news but rather increased demand for Swiss-listed stocks which has helped elevate prices across Swiss equities more broadly. We continue to monitor the situation. Whilst we are not concerned about Roche's valuation, we may look to trim our Swiss exposure elsewhere in the portfolio should market movements cause prices to diverge significantly from our perception of their intrinsic value.

The largest detractor was Henkel with its share price down 4.0% and detracting 0.2% from the overall performance. Henkel continues to demonstrate impressive organic sales growth (particularly in the emerging markets) and we believe the company is currently trading at a price that makes it attractive for long-term owners.

Alnylam (introduced last December) was the best performer, with its share price rising 19.4% (in USD) during June. Honeywell was the weakest performer with its shares falling 5.0% during the month.

There were no outright sales or purchases during June.

The value of the Fund may go down as well as up - you may get back less than you invested.

3 YEAR PERFORMANCE BREAKDOWN

	JAN	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	OCT	NOV	DEC	YTD
2019	0.67%	3.02%	4.61%	2.44%	-0.18%	5.51%	4.09%	0.19%	-0.36%	-3.38%	2.55%	0.11%	20.64%
2020	0.43%	-5.04%	-3.44%	6.53%	5.27%	0.28%	-2.87%	3.12%	1.01%	-4.42%	7.34%	1.82%	9.46%
2021	-1.61%	-0.81%	4.93%	3.89%	1.16%	3.57%							11.45%

Past performance is not a guide to future performance and may not be repeated. Source: Ravenscroft Investment Management Limited, collated 04/06/2021

PERFORMANCE ANALYSIS (Inception date: 1 July 2014)

1 Year	3 Year	5 Year	Inception	Annual Compound Growth Rate
17.7%	51.0%	68.7%	113.1%	11.4%

All figures are based on the Fund's distribution class, inclusive of fees and assuming all dividends are reinvested.

BLUE CHIP PORTFOLIO

FUND	WEIGHTING
Global Brands	
BMW	4.0%
Colgate-Palmolive	2.3%
Diageo	3.3%
Henkel	3.2%
L'Oreal	3.0%
LVMH	3.2%
Nike	1.7%
PepsiCo	2.4%
Richemont	1.7%
Unilever	3.1%
Walt Disney	2.4%
	30.3%
Technology & Innovation	
3M	3.8%
Alphabet	3.3%
Dropbox	1.1%
eBay	1.1%
Honeywell	3.5%
Intel	1.6%
Microsoft	3.0%
Oracle	4.5%
Relx	2.5%
Visa	2.7%
	27.1%
Healthcare	
Alnylam Pharmaceuticals	0.9%
Edward Lifesciences	2.2%
GlaxoSmithKline	1.9%
Illumina	2.5%
Johnson & Johnson	3.3%
Medtronic	3.6%
Novartis	4.1%
Regeneron Pharmaceuticals	2.0%
Roche	4.4%
Sanofi	4.0%
Waters	2.7%
	31.6%
Cash & Equivalents	
Cash	9.2%
JPMorgan Sterling Liquidity	1.8%
	11.0%

DIVIDEND HISTORY

Historic Yield 1.1%

Semi-Annual Dividend Announcement

Ex Date:	1st October 2020	
Rate per O unit:	DIST: £1.14	ACC: £1.25
Rate per I unit:	DIST: £1.12	ACC: £1.24
Ex Date:	1st April 2021	
Rate per O unit:	DIST: £0.92	ACC: £1.02
Rate per I unit:	DIST: £0.90	ACC: £1.00

Dividends are paid a calendar month after each half year
Please note that income levels are not guaranteed and can fluctuate.

KEY POINTS

Dealing Frequency:

Daily (cut-off 5pm GMT one Business Day prior to Dealing Day)

Settlement Period: T+4

Annual Management Fee: 'O' Class - 0.75% (Retail)

'I' Class - 1.5% (Introducer/Advisor)

'S' Class 0.50% (Institutional)

Minimum Investment: 'O' and 'I': £5,000.00 'S' Class: £10,000,000.00

Sedol / ISIN: 'O' Class ACC: BN707P7 / GGO0BN707P73

DIST: BN707Q8 / GGO0BN707Q80

'I' Class ACC: BN707M4 / GGO0BN707M43

DIST: BN707N5 / GGO0BN707N59

'S' Class ACC: BMH70Q3 / GGO0BMH70Q35

DIST: BMH70R4 / GGO0BMH70R42

Trustees: BNP Paribas Securities Services S.C.A. Guernsey Branch

A copy of the Trust Instrument and Scheme Particulars can be obtained by contacting the Administrator:

Praxis Fund Services Limited

T: +44 1481 737600 E: Ravenscroft@PraxisIFM.com

For further information from the Manager, please use the below details:

20 New Street, St Peter Port, Guernsey, GY1 4JG

t +44 (0)1481 729100 w ravenscroftgroup.com

Ravenscroft is a trading name of Ravenscroft Investment Management Limited ("RIML"), which is licensed and regulated by the Guernsey Financial Services Commission to conduct investment business. For all Ravenscroft connected entities, please refer to www.ravenscroftgroup.com/disclaimer. All calls will be recorded and monitored for training and security purposes. This is not an offer or solicitation with respect to the purchase or sale of any security. This fact sheet is intended only to facilitate your discussions with Ravenscroft as to the opportunities available to our clients. The given material is subject to change and, although based upon information which we consider reliable, it is not guaranteed as to accuracy or completeness and it should not be relied upon as such. The material is not intended to be used as a general guide to investing, or as a source of any specific investment recommendations, and makes no implied or express recommendations concerning the manner in which any client's account should or would be handled, as appropriate investment strategies depend upon client's investment objectives. This material does not constitute an offer or solicitation to any person in any jurisdiction in which such offer or solicitation is not authorised or to any person to whom it would be unlawful to make such offer or solicitation. It is the responsibility of any person or persons in possession of this material to inform themselves of and to observe all applicable laws and regulations of any relevant jurisdiction. Prospective investors should inform themselves and take appropriate advice as to any applicable legal requirements and any applicable taxation and exchange control regulations in the countries of their citizenship, residence or domicile which might be relevant to the subscription, purchase, holding, exchange, redemption or disposal of any investments. Ravenscroft does not provide tax advice to its clients and all investors are strongly advised to consult with their tax advisors regarding any potential investment. Opinions expressed are our current opinions as of the date appearing on this material only. Any historical price(s) or value(s) are also only as of the date indicated. While we endeavour to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Certain transactions, including those involving futures, options and high yield securities and investments in emerging markets may give rise to substantial risk and may not be suitable for all investors. Foreign currency denominated investments are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment; such investments are also subject to the possible imposition of exchange control regulations or other laws or restrictions applicable to such investments. Investments referred to in this material are not necessarily available in all jurisdictions, may be illiquid and may not be suitable for all investors. Investors should consider whether an investment is suitable for their particular circumstances and seek advice from Ravenscroft. The price and value of the investments referred to in this material and the income from them may go down as well as up and investors may realise losses on any investments. Past performance is not a guide to future performance. Future returns are not guaranteed and a loss of principal may occur.